Loading...

Purified anti-human IFN-γ Antibody

Pricing & Availability
Clone
4S.B3 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
4S-B3_PE_IFN-y_Antibody_1_091824
PMA/Ionomycin-stimulated human PBMCs were stained with CD3 PE/Cyanine5 and 4S.B3 PE.
  • 4S-B3_PE_IFN-y_Antibody_1_091824
    PMA/Ionomycin-stimulated human PBMCs were stained with CD3 PE/Cyanine5 and 4S.B3 PE.
  • 4SpointB3_PURE_IFN_Antibody_2_051316
    Western blot analysis of 50 ng recombinant human IFN-γ (lane 1), recombinant rat IFN-γ (lane 2), and recombinant mouse IFN-γ (lane 3) using anti-human IFN-γ (clone 4S.B3) antibody followed by HRP anti-mouse IgG secondary antibody.
Compare all formats
Cat # Size Price Quantity Check Availability Save
502501 50 µg 67€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
502502 500 µg 188€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Partially purified, native human IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA - Quality tested
WB - Verified
ICFC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA Capture applications, the antibody should be titrated between 0.25 - 2 µg/ml to determine optimal condition. For Western blotting, the suggested use of this reagent is 0.5 - 2.0 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.
Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.
Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.
Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.

Application References
  1. Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut)
  2. Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut)
  3. Sester M, et al. 2002. J. Virol. 76:3748. (ICFC)
  4. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC)
  5. Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA)
  6. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
  7. Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC)
  8. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
  9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)
Product Citations
  1. Olson BM, et al. 2017. Cancer Immunol Res. 5:1074. PubMed
  2. Law JC, et al. 2021. J Immunol. 206:37. PubMed
  3. Wang D, et al. 2022. Int J Oral Sci. 14:8. PubMed
  4. Alroqi F, et al. 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed
  5. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  6. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
  7. Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed
  8. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  9. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  10. Peeters MJW, et al. 2021. Front Immunol. 12:718863. PubMed
  11. Aravena O, et al. 2017. Arthritis Res Ther. 19:8. PubMed
  12. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  13. Cribbs AP, et al. 2021. Front Immunol. 12:626255. PubMed
  14. Rodriguez-Salazar CA, et al. 2022. Viruses. 14:. PubMed
  15. Salerno F, et al. 2019. J Immunol. 202:714. PubMed
  16. Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed
  17. Park JB, et al. 2019. Mol Cells. 42:597. PubMed
  18. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  19. Kameda M, et al. 2020. PLoS One. 15:e0241719. PubMed
  20. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  21. Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed
  22. Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed
  23. Macmillan ML, et al. 2021. Blood Adv. 5:1425. PubMed
  24. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  25. Chang ZL, et al. 2018. Nat Chem Biol. 0.803472222. PubMed
  26. Sordo-Bahamonde C, et al. 2021. Cancers (Basel). 13:. PubMed
  27. Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed
  28. Iwamoto S, et al. 2007. J Immunol. 179:1449. PubMed
  29. Pompura SL, et al. 2021. J Clin Invest. 131:. PubMed
  30. Stensland ZC, et al. 2022. iScience. 25:103626. PubMed
  31. Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed
  32. Mou W, et al. 2017. BMC Immunol. 18:36. PubMed
RRID
AB_315226 (BioLegend Cat. No. 502501)
AB_315226 (BioLegend Cat. No. 502502)

Antigen Details

Structure
Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID
3458 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Other Formats

View All IFN-γ Reagents Request Custom Conjugation
Description Clone Applications
PE anti-human IFN-γ 4S.B3 ICFC
APC anti-human IFN-γ 4S.B3 ICFC
FITC anti-human IFN-γ 4S.B3 ICFC
Biotin anti-human IFN-γ 4S.B3 ELISA Detection,ELISPOT Detection,ICFC
Purified anti-human IFN-γ 4S.B3 ELISA,WB,ICFC
Alexa Fluor® 488 anti-human IFN-γ 4S.B3 ICFC
Alexa Fluor® 647 anti-human IFN-γ 4S.B3 ICFC
Alexa Fluor® 700 anti-human IFN-γ 4S.B3 ICFC
Pacific Blue™ anti-human IFN-γ 4S.B3 ICFC
PerCP/Cyanine5.5 anti-human IFN-γ 4S.B3 ICFC
APC/Cyanine7 anti-human IFN-γ 4S.B3 ICFC
PE/Cyanine7 anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 421™ anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 570™ anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 605™ anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 650™ anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 711™ anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 785™ anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 510™ anti-human IFN-γ 4S.B3 ICFC
PE/Dazzle™ 594 anti-human IFN-γ 4S.B3 ICFC
APC/Fire™ 750 anti-human IFN-γ 4S.B3 ICFC
PerCP anti-human IFN-γ 4S.B3 ICFC
Brilliant Violet 750™ anti-human IFN-γ 4S.B3 ICFC
KIRAVIA Blue 520™ anti-human IFN-γ Antibody 4S.B3 ICFC
Spark NIR™ 685 anti-human IFN-γ Antibody 4S.B3 ICFC
APC anti-human IFN-γ 4S.B3 ICFC
Spark Blue™ 515 anti-human IFN-γ 4S.B3 ICFC
Spark UV™ 387 anti-human IFN-γ 4S.B3 ICFC
Spark PLUS UV395™ anti-human IFN-γ 4S.B3 ICFC
PE anti-human IFN-γ 4S.B3 ICFC
GMP APC anti-human IFN-γ 4S.B3 ICFC
Go To Top Version: 4    Revision Date: 08/22/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account